Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2009 2
2010 2
2011 2
2012 3
2013 4
2014 4
2015 1
2016 4
2017 2
2019 1
2020 4
2021 5
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Ruo Redda MG, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP; MACH-NC Collaborative Group. Lacas B, et al. Among authors: lee jw. Radiother Oncol. 2021 Mar;156:281-293. doi: 10.1016/j.radonc.2021.01.013. Epub 2021 Jan 27. Radiother Oncol. 2021. PMID: 33515668 Free PMC article.
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Petit C, Lacas B, Pignon JP, Le QT, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar MKB, Lee JW, Ghi MG, Sanguineti G, Temam S, Cheugoua-Zanetsie M, O'Sullivan B, Posner MR, Vokes EE, Cruz Hernandez JJ, Szutkowski Z, Lartigau E, Budach V, Suwiński R, Poulsen M, Kumar S, Ghosh Laskar S, Mazeron JJ, Jeremic B, Simes J, Zhong LP, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P; MACH-NC and MARCH Collaborative Groups. Petit C, et al. Among authors: lee jw. Lancet Oncol. 2021 May;22(5):727-736. doi: 10.1016/S1470-2045(21)00076-0. Epub 2021 Apr 13. Lancet Oncol. 2021. PMID: 33862002
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.
Peipert JD, Zhao F, Lee JW, Shen SE, Ip E, O'Connell N, Carlos RC, Graham N, Smith ML, Gareen IF, Raper PJ, Weiss M, Kumar SK, Rajkumar SV, Cella D, Gray R, Wagner LI. Peipert JD, et al. Among authors: lee jw. JAMA Netw Open. 2024 Mar 4;7(3):e243854. doi: 10.1001/jamanetworkopen.2024.3854. JAMA Netw Open. 2024. PMID: 38536173 Free PMC article. Clinical Trial.
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients.
Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O'Connell N, Hong F, Peipert DJ, Gareen IF, Timsina LR, Gray R, Wagner LI, Carlos RC. Obeng-Gyasi S, et al. Among authors: lee jw. Blood Cancer J. 2022 Apr 1;12(4):53. doi: 10.1038/s41408-022-00648-y. Blood Cancer J. 2022. PMID: 35365604 Free PMC article.
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials.
Streck JM, Lee JW, Walter AW, Rosen RL, Gareen IF, Kircher SM, Herman BA, Carlos RC, Kumar S, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany C, Shanafelt TD, Wagner LI, Land SR, Park ER, Ostroff JS. Streck JM, et al. Among authors: lee jw. Cancer Epidemiol Biomarkers Prev. 2023 Nov 1;32(11):1552-1557. doi: 10.1158/1055-9965.EPI-23-0420. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37410096 Free PMC article.
Biomarkers to monitor drug-induced phospholipidosis.
Baronas ET, Lee JW, Alden C, Hsieh FY. Baronas ET, et al. Among authors: lee jw. Toxicol Appl Pharmacol. 2007 Jan 1;218(1):72-8. doi: 10.1016/j.taap.2006.10.015. Epub 2006 Oct 26. Toxicol Appl Pharmacol. 2007. PMID: 17156806
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Rajdev L, Lee JW, Libutti SK, Benson AB, Fisher GA Jr, Kunz PL, Hendifar AE, Catalano P, O'Dwyer PJ. Rajdev L, et al. Among authors: lee jw. Invest New Drugs. 2022 Dec;40(6):1306-1314. doi: 10.1007/s10637-022-01311-w. Epub 2022 Oct 20. Invest New Drugs. 2022. PMID: 36264382 Free PMC article. Clinical Trial.
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152).
Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. Bradbury AR, et al. Among authors: lee jw. Cancer. 2022 Apr 1;128(7):1381-1391. doi: 10.1002/cncr.34063. Epub 2021 Dec 10. Cancer. 2022. PMID: 34890045 Free PMC article. Clinical Trial.
39 results